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INTRODUCTION 
Cervical lymphadenopathy (CLA) is a common problem 
in clinical practice which poses diagnostic difficulties to 
clinicians [1]. Lymphadenopathy refers to any disease 
process involving lymph nodes that are abnormal in 
size and consistency. Multiple etiologies factors can 
cause cervical lymphadenopathy, the most common of 
which are neoplasia, autoimmune diseases, infection 
and other disorders like Castleman’s disease, sarcoido-
sis, dermatopathic lymphadenitis, histiocytic necrotiz-
ing lymphadenitis, sinus histiocytosis with massive lym-
phadenopathy, Mucocutaneous lymph node syndrome 
(Kawasaki’s disease) [2]. Lymphadenopathy might be 
caused by proliferation of cells intrinsic to the node, 
such as, plasma cells, lymphocytes histiocytes and mon-
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ocytes, or infiltration of cells extrinsic to the node, as 
with neutrophils and malignant cells [3]. Clinical 
presentation generally recurrent fever 38.5>, night 
sweat, weight loss and splenomegaly.  Most clinicians 
treat cervical lymphadenopathy conservatively [4,5]. 
The treatment is often given before biopsy or aspira-
tion is performed. This practice may result in unneces-
sary prescription of antimicrobials. However, the risks 
of surgery often outweigh the potential benefits of a 
brief course of antibiotics [6]. Most enlarged lymph 
nodes are caused by an infectious process. If aspects of 
the clinical picture malignancy, such as weight loss, 
recurrent fever, biopsy should be done sooner for accu-
rate diagnosis [6, 7, 8]. Superior vena cava syndrome 
requires emergency care, including chemotherapy and 
possibly radiation therapy. Fine needle aspiration cytol-
ogy (FNAC), a simple and precise diagnostic procedure, 
used to differentiate between benign and malignant 
peripheral lymphadenopathy. FNAC, as it is obtained 
easily and quickly which is simple and cheap and re-
quires only a specialist input. 
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Aims & Objective: To study various clinical presenta-
tions of cervical lymphadenopathy. To study the man-
agement and outcome of cervical lymphadenopathy 
MATERIALS AND METHOD 
Study design: An observational descriptive prospective 
study  
Ethics approval: The study was approved by the Institu-
tional ethics committee The Fine Needle Aspiration 
Cytology (FNAC) procedure was explained to the pa-
tient in their own vernacular language and written in-
formed consent was taken.   
Study setting: Pravara Institute of Medical Sciences  
Study duration: 2 years  
Sample size: 100 consecutive samples were included as 
per inclusion and exclusion criteria 
Inclusion criteria: All cervical lymphadenopathy pa-
tients between 15 – 40 years of age. 
Exclusion criteria: Previously diagnosed cases and cas-
es already undergoing Anti-tubercular treatment or 
anti-Retroviral treatment, post- radiotherapy were ex-
cluded from the study  
Methodology:   
Proper clinical history was first noted, local and system-
ic examination was performed and a clinical diagnosis 
was made.  Gender wise distribution, presenting symp-
toms, site distribution, and treatment outcome were 
noted. The reactive lymphadenitis were adequately 
managed with antibiotics, anti-inflammatory and local 
treatment. The malignant secondaries and lymphomas 
were staged and treated as per accepted protocols. For 
cases like Carcinoma Larynx and unkown primary were 
referred to specialised oncological centers for further 
management.  For all patients, necessary advice given 
and were asked to attend the surgical outpatient de-
partment for regular follow-up. 
RESULTS 
In present study 100 cases were evaluated for cervical 
lymph node enlargement. All cases were taken for Fine 
Needle Aspiration Cytology (FNAC), but in 10 cases 
FNAC was inconclusive. Excisional biopsy was per-
formed in all 100 cases and finally these cases were 
analyzed in detail.  54% cases were confirmed as tuber-
cular lymphadenitis, 26% as reactive lymphadenitis, 
and 14% as malignant secondaries, 10% cases as Inade-
quate / no opinion and 6% as lymphomas. Thus tuber-
culosis was the commonest etiology for cervical lym-
phadenopathy in the present series. 
 
 




Fig 2. Incidence of presenting symptoms 
(constitutional symptoms)  
DISCUSSION 
54% cases were confirmed as tubercular lymphadenitis, 
26% as reactive lymphadenitis, and 14% as malignant 
secondaries, 10% cases as Inadequate / no opinion and 
6% as lymphomas. Thus tuberculosis was the common-
est etiology for cervical lymphadenopathy in the pre-
sent series. Shamshad Ahmad et al (2005) [10] conclud-
ed the study of FNAC in lymphadenopathy with special 
reference to acid fast staining in cases of tuberculosis. 
They found that 53.6% cases were benign reactive na-
ture, 32.8% were tubercular etiology and 13.6% were 
malignant lymphadenopathy. Out of 328 cases of    
Fig 1: Cervical lymph node enlargement 
Gender No of Cases (%) 
Male 52 (52%) 
Female 48 (48%) 
Total 100 (100%) 
Satish et al.  Etiological factors, clinical presentations and treatment outcome of cervical lymphadenopathy 
Int. j. clin. biomed. res. 2018;4(2):42-46. 
 44 
 
tubercular lymphadenopathy, Z-N positivity for acid 
fast bacilli was found in 152 cases (46.4%). 
There were 80 non-neoplastic lesions and 20 neoplastic 
lesions in the present study. Presence of clinical symp-
toms has limited significance in clinical diagnosis as 
constitutional symptoms are variable and not con-
sistant with specific disease. In tuberculosis, level V was 
most commonly affected (33.33%) followed by Level II 
Level of lymph nodes TBL RL Lymphomas Metastatic secondaries Total 
Level 1 9 10 0 0 19 
Level 2 14 6 3 7 30 
Level 3 7 1 0 4 12 
Level 4 6 2 1 1 10 
Level 5 18 7 2 2 29 
Level 6 0 0 0 0 0 
Total 54 26 6 14 100 
Table 2. Site distribution (as per Level of Lymph nodes)  
Primary site of Malignancy HPE in cervical Lymphadenopathy No. of cases 
Thyroid Papillary 2 
Tongue Squamous cell carcinoma 4 
Nasopharynx Squamous cell carcinoma 1 
Larynx Squamous cell carcinoma 1 
Esophagus Squamous cell carcinoma 2 
Stomach Adenocarcinoma 1 
Lung Large cell Carcinoma 1 
Unknown Squamous cell carcinoma 1 
Adenocarcinoma 1 
Total   14 
Table 3. Distribution of primaries in cases on secondaries in cervical region  
Diagnosis No. of cases Treatment No. of cases 
Outcome 
Improved Expired 
Tubercular lymphadenitis 54 





5 5 0 
Reactive 26 Antibiotics 26 26 0 
Metastatic secondaries 14 
Chemotherapy/ 5 3 2 
Operated 6 5 1 
Referred 3 Not Followed 0 
Hodgkin’s Lymphoma 1 Chemotherapy 1 1 0 
Non-Hodgkin’s Lymphoma 5 Chemotherapy 5 5 0 
Table 4. Treatment and Outcome 
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(25.92%). In contrast, in secondaries Level II group was 
most commonly involved (50%) and similarly in lym-
phomas Level II group was involved most commonly of 
the 6 cases of histopathologically confirmed lympho-
mas, 5 were Non-Hodgkin’s variety and 1 was Hodg-
kin’s lymphoma. 
In the Jha BC et al (2001) series, Level II group was most 
involved in tuberculosis [11] . The result of this study is 
comparable to the study made by Baskota DK et al 
study, wherein tuberculosis Level V lymph nodes is 
most commonly involved [12] . 
Chest X-ray positivity was seen in 7.4% of cases of pre-
sent study. The studies made by Jha BC et al (2001) 
series showed 16% positivity [11]. 
In the present study, commonest site of primary in cas-
es of metastatic Secondaries was tongue followed by 
oesophagus and thyroid. The commonest site of prima-
ry in a case of malignant secondary was lungs and pan-
creas in the studies by Linderman et al [13]. In the 
study by Osama Gaber et al [14], it was possible to es-
tablish primary in 86.7% whereas in the present study it 
was only 85.71%. In rest of the cases, primary could not 
be diagnosed because of limited resources of our hos-
pital. 
Treatment: After proper diagnosis confirmed by Histo-
pathology (biopsy), treatment constituted properly- 
Cases of Tubercular Lymphadenitis (49 cases) were 
Started on Anti-tubercular treatment, all were showed 
improvement in symptoms. 
After coming to a diagnosis, treatment was instituted 
appropriately.  For reactive lymphadenitis, tubercular 
lymphadenitis medical treatment was instituted. In this 
study, patients with tubercular Lymphadenitis were 
started on antitubercular treatment as per Categories 
while patients of Tubercular Lymphadenitis with cold 
abscess were treated with Incision & Drainage  and 
antitubercular treatment. In the treatment of tubercu-
lar lymphadenitis similar findings as in present study 
was obtained from Jha BC et al, where short course 
chemotherapy was given with no recurrence [11].  
Anti-tubercular treatment for tubercular lymphadenitis 
was highly satisfactory with improvement in almost all 
patients.  Surgery was restricted as an adjuvant to 
chemotherapy, as diagnostic biopsy, for treatment of 
abscess/sinuses and for a lymph nodes that do not re-
solve with chemotherapy. Non-tuberculous non-
neoplastic lesions were best managed conservatively. 
The neoplastic lesions of lymph nodes require speciality 
oncology protocols. 
Cases of Tubercular Lymphadenitis with Lymph node 
abscess (5 cases) were treated with Incision and Drain-
age and started on Anti-tubercular treatment, all 
showed improvement in symptoms on follow up. 
Cases of Reactive lymphadenitis (26 cases) started on 
antibiotics, all recovered well. Among 14 Cases of Met-
astatic secondaries, 5 cases were given Chemothera-
Radiotherapy after expert oncologist opinion out of 
which 3 showed improved symptoms and 2 were ex-
pired, 6 cases were operated out of which 5 showed 
improved symptoms and 1 expired post operatively, 3 
cases were referred to specialized oncological and   
oncosurgical center for further management. All 6 Lym-
phoma cases were started on chemotherapy after ex-
pert oncologist opinion showed improvement in symp-
toms.   
CONCLUSION 
Tuberculosis was the commonest etiology for cervical 
lymphadenopathy, commonest site of primary in cases 
of metastatic, secondaries was tongue followed by oe-
sophagus and thyroid. Anti-tubercular treatment for 
tubercular lymphadenitis was highly satisfactory with 
improvement in almost all patients.  Surgery was re-
stricted as an adjuvant to chemotherapy, as diagnostic 
biopsy, for treatment of abscess/sinuses and for a 
lymph nodes that do not resolve with chemotherapy. 
Non-tuberculous non-neoplastic lesions can be best 
managed by  conservatively. 
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